In early 1997, Cephalon, waited for the FDA panel whether its drug, Myotrophin, is approved. If the drug is approved, the company may require substantial additional funding for commercialization, as well as to buy the rights to it (which were previously sold to finance its development.) CFO of considering various financing strategies, including options to purchase its own shares of the company and pay for the option by issuing shares at the moment. "Hide
by Peter Tufano, Geoffrey Verter, Markus F. Mullarkey Source: Harvard Business School 18 pages. Publication Date: April 13, 1998. Prod. #: 298116-PDF-ENG
Related Case Solutions & Analyses:
Northboro Machine tools Corporation (v. 1.0)
The Gold Story
Equity-Worthiness and Equity-Willingness: Key Factors In Private Equity Deals
Introduction to Short Selling
The Dodd-Frank Act and Its Impact
Ayudhya Allianz C.P.: The i2s Initiative
Bicicleta Ferreira Limitada Redux
Boblbee (D): The Urban Backpack
Bukser & Berging (A): The Escort Fin First Tractor Tug Project
Cemex Way To Profitable Growth: Leveraging Post-Merger Integration And Best-Practice Innovation
